@article{e5a2f0046c1f482a86afb791dbb7e5ed,
title = "The need to assess financial adverse events",
author = "Nastoupil, {Loretta J.} and Vinay Prasad and Flowers, {Christopher R.}",
note = "Funding Information: LJN has received personal fees from Bayer, Celgene, Genentech, Roche, Gilead, Merck, Novartis, Spectrum Pharmaceuticals, and TG Therapeutics and research support from Celgene, Abbvie, Genentech, Roche, Janssen, and Karus, outside the submitted work. VP has received grants from the Laura and John Arnold Foundation and royalties for a book from Johns Hopkins Press, outside the submitted work. CRF has received consultancy fees from Spectrum, Celgene, Optum Rx, Seattle Genetics, GIlead, Bayer, Karyopharm, AstraZeneca, and Beigene; has acted as a consultant for Genentech/Biogen-Idec/Roche (unpaid) and Millennium/Takeda (unpaid); has received research funding from AbbVie, Acerta, Celgene, Gilead Sciences, Infinity Pharmaceuticals, Janssen Pharmaceutical, Millennium/Takeda, Spectrum Onyx Pharmaceuticals, Phamacyclics, and the National Institutes of Health; and has received payment for development of educational presentations from Clinical Care Options, Educational Concepts, PRIME Oncology, Research to Practice, outside the submitted work.",
year = "2018",
month = nov,
doi = "10.1016/S2352-3026(18)30072-3",
language = "English (US)",
volume = "5",
pages = "e508--e509",
journal = "The Lancet Haematology",
issn = "2352-3026",
publisher = "Lancet Publishing Group",
number = "11",
}